Confronting Cancer with Clinical Trials
Brain Tumor Clinical Trials
Below is a list of brain tumor clinical trials run by the Neuro-Oncology and Neurosurgery departments at MD Anderson. We have clinical trials for many brain tumors, including glioblastoma, meningioma, anaplastic astrocytoma and brain metastases.
Trial availability may change without notice. Individual trial spots may open or close without notice. Click on the study link for detailed information about each clinical trial.
Last updated 11/1/2018
Glioblastoma - newly diagnosed
Study: 2018-0044
Phase II
Treatment agent(s): GDC-0084
Newly diagnosed MGMT unmethylated glioblastoma
NIH link: NCT No: NCT03522298
Study: 2017-0555
Phase I
Treatment agent(s): EDO-S101, radiation
Newly diagnosed MGMT unmethylated, IDH wildtype glioblastoma
This trial is only available at MD Anderson
NIH link: NCT No: NCT03452930
Study: 2016-0867
Phase I/II
Treatment agent(s): Atezolizumab, radiation, Temozolomide
Newly diagnosed glioblastoma
This trial is only available at MD Anderson
NIH link: NCT No: NCT03174197
Glioblastoma - recurrent
Study: 2018-0045
Phase II
Treatment agent: ONC201
Recurrent high-grade gliomas with H3 K27M mutation
NIH link: NCT No: NCT03295396
Study: 2017-0619
Phase II
Treatment agent: Bevacizumab, DSP-7888
Recurrent glioblastoma
NIH link: NCT No: NCT03149003
Study: 2012-0358
Phase I
Treatment agent: WP1066
Recurrent malignant glioma and melanoma brain metastasis
This trial is only available at MD Anderson
NIH link: NCT No: NCT01904123
Study: 2017-0570
Phase I
Treatment agent: Ad-RTS-hIL-12 +Veledimex
Recurrent glioblastoma
NIH link: NCT No: NCT02026271
Study: 2015-0864
Phase II
Treatment agent: Crenolanib
Recurrent glioblastoma with PDGFRA gene amplification
This trial is only available at MD Anderson
NIH link: NCT No: NCT02626364
Study: 2016-0252
Phase II
Treatment agent: VAL-083
Unmethylated MGMT recurrent glioblastoma
This trial is only available at MD Anderson
NIH link: NCT No: NCT02717962
Study: 2016-0433
Phase II
Treatment agent: Adenovirus (DNX-2401) with Pembrolizumab
Recurrent glioblastoma or gliosarcoma
NIH link: NCT No: NCT02798406
Study: 2016-0443
Phase II
Treatment agents: Laser Interstitial Thermal Therapy and Lomustine
Recurrent glioblastoma or grade III IDH-wildtype anaplastic astrocytoma
This trial is only available at MD Anderson
NIH link: NCT03022578
Study: 2016-0859
Phase II
Treatment agent: Pembrolizumab
Recurrent malignant gliomas with a hypermutator phenotype
NIH link: NCT No: NCT02658279
Anaplastic glioma (grade III) – recurrent
Study: 2018-0045
Phase II
Treatment agent: ONC201
Recurrent high-grade gliomas with H3 K27M mutation
NIH link: NCT No: NCT03295396
Study: 2012-0358
Phase I
Treatment agent: WP1066
Recurrent malignant glioma and melanoma brain metastasis
This trial is only available at MD Anderson
NIH link: NCT No: NCT01904123
Study: 2016-0330
Phase III
Treatment agent: Lomustine and Eflornithine
First recurrence of grade III anaplastic astrocytoma
NIH link: NCT No: NCT02796261
Study: 2016-0859
Phase II
Treatment agent: Pembrolizumab
Recurrent malignant gliomas with a hypermutator phenotype
NIH link: NCT No: NCT02658279
Craniopharyngioma
Study: #ALLIANCEA071601
Phase II
Treatment agent: Cobimetinib, Vemurafenib
BRAF V600E mutation positive Papillary Craniopharyngiomas
NIH link: NCT03224767
Brain metastases and/or leptomeningeal disease
Study: 2012-0358
Phase I
Treatment agent: WP1066
Recurrent malignant glioma and melanoma brain metastasis
This trial is only available at MD Anderson
NIH link: NCT No: NCT01904123
Study: ALLIANCEA221208
Phase II
Treatment agent: Bevacizumab
Radionecrosis after radiosurgery for brain metastases
NIH link: NCT No: NCT02490878
Non-therapeutic and/or symptom control
Study: 2012-0441
Prospective assessment of correlative biomarkers in CNS patients (the PROACTIVE Program), a biomarker-driven program for clinical trial development for newly diagnosed and recurrent CNS patients
All Clinical Trials
MD Anderson patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
Several other departments, including Radiation Oncology and Investigational Cancer Therapeutics, also offer clinical trials that may be open to brain tumor patients.